{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:59Z","timestamp":1772166599490,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Letten Foundation Zimbabwe"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["16\/136\/33"],"award-info":[{"award-number":["16\/136\/33"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fogarty HIV Implementation Science Research Training Program","award":["1D43TW009539-03"],"award-info":[{"award-number":["1D43TW009539-03"]}]},{"name":"Fogarty International Clinical, Operational and Health Services Research and Training Award","award":["2U2RTW007367-01"],"award-info":[{"award-number":["2U2RTW007367-01"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["2R01 AI098472"],"award-info":[{"award-number":["2R01 AI098472"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adolescents experience higher levels of non-adherence to HIV treatment. Drug concentration in hair promises to be reliable for assessing exposure to antiretroviral (ARV) drugs. Pharmacokinetic modelling can explore utility of drug in hair. We aimed at developing and validating a pharmacokinetic model based on atazanavir\/ritonavir (ATV\/r) in hair and identify factors associated with variabilities in hair accumulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We based the study on secondary data analysis whereby data from a previous study on Zimbabwean adolescents which collected hair samples at enrolment and 3\u00a0months follow-up was used in model development. We performed model development in NONMEM (version 7.3) ADVAN 13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There is 16% \/ 18% of the respective ATV\/r in hair as a ratio of steady-state trough plasma concentrations. At follow-up, we estimated an increase of 30% \/42% of respective ATV\/r in hair. We associated a unit increase in adherence score with 2% increase in hair concentration both ATV\/r. Thinner participants had 54% higher while overweight had 21% lower atazanavir in hair compared to normal weight participants. Adolescents receiving care from fellow siblings had atazanavir in hair at least 54% less compared to other forms of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The determinants of increased ATV\/r concentrations in hair found in our analysis are monitoring at follow up event, body mass index, and caregiver status. Measuring drug concentration in hair is feasibly accomplished and could be more accurate for monitoring ARV drugs exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-020-00437-y","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T08:06:34Z","timestamp":1596441994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-5954","authenticated-orcid":false,"given":"Bernard","family":"Ngara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simbarashe","family":"Zvada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariro Dianah","family":"Chawana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babill","family":"Stray-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Fungai Brian","family":"Nhachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simbarashe","family":"Rusakaniko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"437_CR1","unstructured":"Global and Regional Trends. UNICEF DATA. Available from: \/\/data.unicef.org\/topic\/hivaids\/global-regional-trends\/. [cited 2017 Dec 28]."},{"key":"437_CR2","unstructured":"ZWE_2018_countryreport.pdf. Available from: http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/ZWE_2018_countryreport.pdf. [cited 2019 Jan 21]."},{"issue":"3","key":"437_CR3","first-page":"21","volume":"136","author":"DL Paterson","year":"2002","unstructured":"Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2002;136(3):21\u201330.","journal-title":"Ann Intern Med"},{"issue":"6","key":"437_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"issue":"1","key":"437_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5897\/JAHR2016.0406","volume":"9","author":"TD Chawana","year":"2017","unstructured":"Chawana TD, Katzenstein D, Nathoo K, Ngara B, CFB N. Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir\/ritonavir-based second line antiretroviral treatment at a public health clinic. J AIDS HIV Res. 2017;9(1):17\u201330.","journal-title":"J AIDS HIV Res"},{"key":"#cr-split#-437_CR6.1","doi-asserted-by":"crossref","unstructured":"Makadzange AT, Higgins-Biddle M, Chimukangara B, et al. Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe. Plos One. 2015;10","DOI":"10.1371\/journal.pone.0144057"},{"key":"#cr-split#-437_CR6.2","unstructured":"(12) Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4678607\/. [cited 2017 June 13]."},{"issue":"11","key":"437_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5897\/IJMMS2015.1164","volume":"8","author":"A Zeleke","year":"2016","unstructured":"Zeleke A. Prevalence of antiretroviral treatment failure and associated factors in HIV infected children on antiretroviral therapy at Gondar University hospital, retrospective cohort study. Int J Med Med Sci. 2016;8(11):125\u201332.","journal-title":"Int J Med Med Sci"},{"key":"#cr-split#-437_CR8.1","doi-asserted-by":"crossref","unstructured":"Yassin S, Gebretekle GB. Magnitude and predictors of antiretroviral treatment failure among HIV-infected children in Fiche and Kuyu hospitals, Oromia region, Ethiopia: a retrospective cohort study. Pharmacol Res Perspect. 2017;5","DOI":"10.1002\/prp2.296"},{"key":"#cr-split#-437_CR8.2","unstructured":"(1) Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5461638\/. [cited 2017 June 13]."},{"key":"#cr-split#-437_CR9.1","doi-asserted-by":"crossref","unstructured":"Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc. 2015;18","DOI":"10.7448\/IAS.18.1.20049"},{"key":"#cr-split#-437_CR9.2","unstructured":"(1) Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4575412\/. [cited 2017 June 13]."},{"key":"437_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2334-12-21","volume":"12","author":"MD Nglazi","year":"2012","unstructured":"Nglazi MD, Kranzer K, Holele P, et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis. 2012;12:21.","journal-title":"BMC Infect Dis"},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12884-015-0697-7","volume":"15","author":"S Okawa","year":"2015","unstructured":"Okawa S, Chirwa M, Ishikawa N, et al. Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. BMC Pregnancy Childbirth. 2015;15:258.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"437_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/QAI.0b013e31829f05ac","volume":"64","author":"K Bonner","year":"2013","unstructured":"Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 1999. 2013;64(1):74\u20138.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"issue":"2","key":"437_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s10461-010-9825-6","volume":"15","author":"AD M\u00fcller","year":"2011","unstructured":"M\u00fcller AD, Jaspan HB, Myer L, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011;15(2):422\u201331.","journal-title":"AIDS Behav"},{"issue":"6","key":"437_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.pedn.2009.07.002","volume":"25","author":"G Burack","year":"2010","unstructured":"Burack G, Gaur S, Marone R, Petrova A. Adherence to antiretroviral therapy in pediatric patients with human immunodeficiency virus (HIV-1). J Pediatr Nurs. 2010;25(6):500\u20134.","journal-title":"J Pediatr Nurs"},{"issue":"1","key":"437_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/QAI.0000000000001452","volume":"76","author":"TD Chawana","year":"2017","unstructured":"Chawana TD, Gandhi M, Nathoo K, et al. Defining a cut-off for atazanavir in hair samples associated with virological failure among adolescents failing second-line antiretroviral treatment. J Acquir Immune Defic Syndr. 2017;76(1):55\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"437_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-1241.2001.tb11062.x","volume":"55","author":"JH Beumer","year":"2001","unstructured":"Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract. 2001;55(6):353\u20137.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"437_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.7326\/0003-4819-137-8-200210150-00016","volume":"137","author":"M Gandhi","year":"2002","unstructured":"Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med. 2002;137(8):696\u20137.","journal-title":"Ann Intern Med"},{"issue":"4","key":"437_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/QAD.0b013e328325a4a9","volume":"23","author":"M Gandhi","year":"2009","unstructured":"Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair samples strongly predict Virologic responses to HIV treatment. AIDS Lond Engl. 2009;23(4):471\u20138.","journal-title":"AIDS Lond Engl"},{"issue":"10","key":"437_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/cir131","volume":"52","author":"M Gandhi","year":"2011","unstructured":"Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(10):1267\u201375.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"3","key":"437_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/QAI.0000000000000154","volume":"66","author":"MD Hickey","year":"2014","unstructured":"Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr 1999. 2014;66(3):311\u20135.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"issue":"1","key":"437_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/QAD.0b013e3280118486","volume":"21","author":"X Duval","year":"2007","unstructured":"Duval X, Peytavin G, Breton G, et al. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir\/ritonavir combination. AIDS Lond Engl. 2007;21(1):106\u20138.","journal-title":"AIDS Lond Engl."},{"issue":"1","key":"437_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0379-0738(93)90267-E","volume":"63","author":"DA Kidwell","year":"1993","unstructured":"Kidwell DA, Blank DL. Comments on the paper by W.a. Baumgartner and V.a. Hill: sample preparation techniques. Forensic Sci Int. 1993;63(1):137\u201343.","journal-title":"Forensic Sci Int"},{"issue":"1","key":"437_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0379-0738(94)01625-F","volume":"70","author":"RL DuPont","year":"1995","unstructured":"DuPont RL, Baumgartner WA. Drug testing by urine and hair analysis: complementary features and scientific issues. Forensic Sci Int. 1995;70(1):63\u201376.","journal-title":"Forensic Sci Int"},{"issue":"1","key":"437_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0379-0738(93)90269-G","volume":"63","author":"WA Baumgartner","year":"1993","unstructured":"Baumgartner WA, Hill VA. Comments on the paper by David L. Blank and David a. Kidwell: external contamination of hair by cocaine: an issue in forensic interpretation. Forensic Sci Int. 1993;63(1):157\u201360.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"437_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/tc.11.3.176","volume":"11","author":"WK Al-Delaimy","year":"2002","unstructured":"Al-Delaimy WK. Hair as a biomarker for exposure to tobacco smoke. Tob Control. 2002;11(3):176\u201382.","journal-title":"Tob Control"},{"issue":"4","key":"437_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejfs.2015.12.002","volume":"6","author":"H Khajuria","year":"2016","unstructured":"Khajuria H, Nayak BP. Detection and accumulation of morphine in hair using GC\u2013MS. Egypt J Forensic Sci. 2016;6(4):337\u201341.","journal-title":"Egypt J Forensic Sci"},{"issue":"1","key":"437_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0379-0738(98)00003-6","volume":"92","author":"R Kronstrand","year":"1998","unstructured":"Kronstrand R, Grundin R, Jonsson J. Incidence of opiates, amphetamines, and cocaine in hair and blood in fatal cases of heroin overdose. Forensic Sci Int. 1998;92(1):29\u201338.","journal-title":"Forensic Sci Int"},{"issue":"1\u20133","key":"437_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.forsciint.2011.10.014","volume":"218","author":"M Minoli","year":"2012","unstructured":"Minoli M, Angeli I, Ravelli A, Gigli F, Lodi F. Detection and quantification of 11-nor-\u03949-tetrahydrocannabinol-9-carboxylic acid in hair by GC\/MS\/MS in negative chemical ionization mode (NCI) with a simple and rapid liquid\/liquid extraction. Forensic Sci Int. 2012;218(1\u20133):49\u201352.","journal-title":"Forensic Sci Int"},{"issue":"8","key":"437_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1373\/clinchem.2011.164822","volume":"57","author":"D Lee","year":"2011","unstructured":"Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem. 2011;57(8):1127\u201336.","journal-title":"Clin Chem"},{"issue":"5","key":"437_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jat\/29.5.319","volume":"29","author":"M Schaffer","year":"2005","unstructured":"Schaffer M, Hill V, Cairns T. Hair analysis for cocaine: the requirement for effective wash procedures and effects of drug concentration and hair porosity in contamination and decontamination. J Anal Toxicol. 2005;29(5):319\u201326.","journal-title":"J Anal Toxicol"},{"key":"437_CR31","unstructured":"Drugs-in-Hair-FAQ.pdf. Available from: http:\/\/www.vifm.org\/wp-content\/uploads\/2015\/06\/Drugs-in-Hair-FAQ.pdf. [cited 2017 Jul 4]."},{"key":"437_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40360-015-0004-2","volume":"16","author":"M Dhoro","year":"2015","unstructured":"Dhoro M, Zvada S, Ngara B, et al. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015;16:4.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"437_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","volume":"64","author":"C Nyakutira","year":"2008","unstructured":"Nyakutira C, R\u00f6shammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G\u2192T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357\u201365.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"437_CR34","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","volume":"68","author":"JK Mukonzo","year":"2009","unstructured":"Mukonzo JK, R\u00f6shammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009;68(5):690\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"29","key":"437_CR35","first-page":"2188","volume":"6","author":"T Nemaura","year":"2012","unstructured":"Nemaura T, Nhachi C, Masimirembwa C. Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV\/AIDS and TB treatment: implications for individualising therapy. Afr J Pharm Pharmacol. 2012;6(29):2188\u201393.","journal-title":"Afr J Pharm Pharmacol"},{"issue":"6","key":"437_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1365-2125.2011.04035.x","volume":"72","author":"F Foissac","year":"2011","unstructured":"Foissac F, Blanche S, Dollfus C, et al. Population pharmacokinetics of atazanavir\/ritonavir in HIV-1-infected children and adolescents. Br J Clin Pharmacol. 2011;72(6):940\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"437_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bcp.12101","volume":"76","author":"C Zhang","year":"2013","unstructured":"Zhang C, Denti P, Decloedt EH, Ren Y, Karlsson MO, McIlleron H. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. Br J Clin Pharmacol. 2013;76(5):741\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"437_CR38","unstructured":"NONMEM\u00ae - ICON plc. Available from: http:\/\/www.iconplc.com\/innovation\/nonmem\/. [cited 2017 Jun 20]."},{"issue":"6","key":"437_CR39","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol. 2013;2(6):e50.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"437_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"437_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1473-3099(13)70363-3","volume":"14","author":"ED Lowenthal","year":"2014","unstructured":"Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis. 2014;14(7):627\u201339.","journal-title":"Lancet Infect Dis"},{"key":"437_CR42","doi-asserted-by":"publisher","first-page":"18579","DOI":"10.7448\/IAS.16.1.18579","volume":"16","author":"AL Agwu","year":"2013","unstructured":"Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. J Int AIDS Soc. 2013;16:18579.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"437_CR43","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/09540121.2017.1391986","volume":"30","author":"MW Gichane","year":"2018","unstructured":"Gichane MW, Sullivan KA, Shayo AM, et al. Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. AIDS Care. 2018;30(6):701\u20135.","journal-title":"AIDS Care"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-020-00437-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00437-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T02:29:24Z","timestamp":1696472964000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00437-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00437-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-15958\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-15958\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-15958\/v3","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study got approval to use secondary data from the institutional and national ethical review committees [Joint Research Ethics Committee (JREC\/101\/18) and Medical Research Council of Zimbabwe (MRCZ\/A\/2301) respectively].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}